Literature DB >> 10894093

The ovarian and cervical regions of the rat uterus display a different contractile response to serotonin and prostaglandin F2alpha. I. The estrous cycle.

M V Oropeza1, H Ponce Monter, M Reynoso Isla, M G Campos.   

Abstract

In pharmacological studies using isolated tissues, the sensitivity to different agonists may vary depending on the anatomical region. The aim of the present study was to evaluate the in vitro contractile response to serotonin, prostaglandin F2alpha, and oxytocin of the ovarian and the cervical uterine segments isolated from rats in the four different stages of the rat estrous cycle. Non-cumulative curves were recorded for both, the ovarian and the cervical uterine segments. The cervical portion displayed a higher contractile response to serotonin and a lower response to PGF2alpha than the ovarian portion. Oxytocin induced similar responses in both uterine segments. The uterine ovarian segment displayed a similar sensitivity to serotonin in all the estrous cycle stages, whereas in the cervical segment, influenced by estrogens in diestrus and proestrus, an increase in contractility was observed. According to these findings, serotonin might participate in the spermatozoa transport toward the oviduct. The higher response of the ovarian portion to prostaglandin F2alpha is in line with its role during labor and delivery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894093     DOI: 10.1016/s0024-3205(00)80010-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

Review 1.  The expanded biology of serotonin.

Authors:  Miles Berger; John A Gray; Bryan L Roth
Journal:  Annu Rev Med       Date:  2009       Impact factor: 16.048

2.  Loss of function of endothelin-2 leads to reduced ovulation and CL formation.

Authors:  Joseph A Cacioppo; Sang Wook Oh; Hey-young Kim; Jongki Cho; Po-Ching Patrick Lin; Masashi Yanagisawa; CheMyong Ko
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.